Zalutumumab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameZalutumumab
Drug Alias Name扎鲁妥木单抗Zalutumumabum扎鲁木单抗扎芦木单抗HuMax-EGFr +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungHead and Neck NeoplasmsColorectal Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[25] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGenmab A/S
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGenmab A/S
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungHead and Neck NeoplasmsColorectal Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG